enGene Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview

enGene Therapeutics

29/05/2026 13:38

enGene Therapeutics Inc ENGN.OQ ENGN.O is expected to  show no change in quarterly revenue when it reports  results on June 1 (estimated) for the period ending April 30 2026

​LSEG's mean analyst estimate for enGene Therapeutics Inc is for a loss of 47 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 8 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for enGene Therapeutics Inc is $4.50, about 152.8% above its last closing price of $1.78
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Jan. 31 2026
-0.57
-0.56
-0.44
Beat
21.4
Oct. 31 2026
-0.57
-0.57
-0.73
Missed
-28.5
Jul. 31 2025
-0.51
-0.50
-0.57
Missed
-13.7​
Apr. 30 2025
-0.53
-0.50
-0.51
Missed
-2.4
​​Jan. 31 2025
-0.36
-0.37
-0.48
Missed
-29.3
Oct. 31 2024
-0.39
-0.38
-0.34
Beat
10​
Jul. 31 2024
-0.43
-0.37
-0.32
Beat
14.7
Apr. 30 2024
-0.26
-0.26
-0.38
Missed
-45
This summary was machine generated May 29 at 12:38 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)